Metformin/voglibose

Drug Profile

Metformin/voglibose

Alternative Names: CJ-30001; CJ-30002; HKB-0701/SLM-0807; SLM-0807/HKB-0701; Voglibose/metformin; Vogmet

Latest Information Update: 21 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CJ Cheiljedang Corp.
  • Developer CJ HealthCare
  • Class Antihyperglycaemics; Biguanides; Inositol phosphates; Small molecules; Sugar alcohols
  • Mechanism of Action Alpha-glucosidase inhibitors; AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Jul 2012 CJ Cheiljedang Corporation completes a phase III trial in Type-2 diabetes mellitus in South Korea (NCT01370707)
  • 30 Apr 2011 Phase-III clinical trials in Type-2 diabetes mellitus in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top